Advertisement

Supply Chain



President-elect Donald Trump could significantly affect the Food and Drug Administration's oversight of the drug industry, according to John LaMattina, former president of Pfizer Global Research and Development.

The Food and Drug Administration recently rejected Dynavax Technology Corp.'s hepatitis B drug, Heplisav-B, for the second time in three years, reports Reuters.

Advertisement

Most Read

Advertisement
Advertisement